Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy in first-line metastatic non-squamous NSCLC with PD-L1 expression
NL-OMON59324Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of rilvegostomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Overall survival and Progression-free survival. Started Apr 2025; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59324.